Poly Medicure · NSE: POLYMED · BSE: 531768

Q3 FY24 results · Oct–Dec 2023

Poly Medicure reported revenue from operations of ₹339.60 crore (up 19.2% from Q3 FY23) and net profit of ₹65.02 crore (up 30.0% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.

Consolidated · ₹ crore
ItemQ3 FY24Q3 FY23YoYQ2 FY24QoQ
Revenue from operations339.60284.83+19.2%337.29+0.7%
Other income16.5714.43+14.8%14.09+17.6%
Total income356.17299.26+19.0%351.39+1.4%
Profit before share of associates & JVs and tax87.1166.43+31.1%80.11+8.7%
Share of profit/(loss) of associates & JVs0.710.360.84
Net profit for the period65.0250.01+30.0%62.19+4.5%
EPS, basic (₹)6.785.21+30.1%6.48+4.6%
Net margin (%)19.117.618.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ3 FY24Q3 FY23YoYQ2 FY24QoQ
Revenue from operations320.86271.74+18.1%319.90+0.3%
Other income16.5614.35+15.4%12.78+29.6%
Total income337.43286.09+17.9%332.68+1.4%
Profit before tax82.0964.32+27.6%77.96+5.3%
Net profit for the period61.4647.54+29.3%59.21+3.8%
EPS, basic (₹)6.414.95+29.5%6.17+3.9%
Net margin (%)19.217.518.5
Consolidated
Filed with BSE
01 Feb 2024, 12:02 IST
Board meeting
31 Jan 2024
Period
01 Oct 2023 to 31 Dec 2023
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
01 Feb 2024, 12:02 IST
Board meeting
31 Jan 2024
Period
01 Oct 2023 to 31 Dec 2023
Review status
Unaudited
Source
XBRL filing on BSE